Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

Rhea-AI Summary

Protalix BioTherapeutics (NYSE: PLX) announced its participation in the 17th Annual WORLD Symposium scheduled for February 8-12, 2021. The company will deliver an oral presentation and a poster presentation featuring data from the BRIDGE Phase III study on pegunigalsidase alfa for Fabry disease. The oral presentation will occur on February 10, 2021, at 1:24 PM EST, while the poster session takes place from 2:30 to 3:30 PM EST. Protalix is also advancing its pipeline, which includes therapeutic proteins for various conditions.

Positive

• Participation in a major symposium can increase visibility and credibility in the industry.
• Presentation of Phase III study data highlights progress in the development of pegunigalsidase alfa.

Negative

• None.

CARMIEL, Israel, Feb. 1, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell-based protein expression system, today announced that it will deliver an oral presentation and a poster presentation at the 17^th Annual WORLDSymposium™, a research conference dedicated to lysosomal diseases being held virtually February 8-12, 2021. The oral and poster presentations will highlight data generated from the Company's BRIDGE Phase III 12 month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa.

Presentation Details:

Title: Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study

Presenter: Ales Linhart, MD, Charles University, Praha, Czech Republic, a principal investigator in the Company's Phase III clinical trials of PRX-102 for the potential treatment of Fabry disease

Date/Time: The oral presentation is scheduled for Wednesday, February 10, 2021 at 1:24 PM EST

The poster presentation is scheduled for Wednesday, February 10, 2021 from 2:30 to 3:30 PM EST (Poster # 141)

Additional details can be found on the WORLDSymposium website at https://worldsymposia.org/. Copies of the presentation materials will be made available on the Company's website under the Presentations tab in the Investors section at the time of the poster session.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.

Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α-Galactosidase-A protein for the proposed treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-announces-presentations-at-the-17th-annual-worldsymposium-2021-301218819.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

What is Protalix BioTherapeutics presenting at the WORLD Symposium?

Protalix BioTherapeutics is presenting data from the BRIDGE Phase III study on pegunigalsidase alfa for treating Fabry disease.

When is the oral presentation by Protalix BioTherapeutics at the WORLD Symposium?

The oral presentation is scheduled for February 10, 2021, at 1:24 PM EST.

What are the details of the poster presentation by Protalix BioTherapeutics?

The poster presentation is on February 10, 2021, from 2:30 to 3:30 PM EST, featuring poster #141.

What is pegunigalsidase alfa?

Pegunigalsidase alfa is a modified version of the recombinant human α-Galactosidase-A protein being developed for Fabry disease.

What is the significance of the BRIDGE Phase III study for Protalix BioTherapeutics?

The BRIDGE Phase III study is crucial for evaluating the safety and efficacy of pegunigalsidase alfa, impacting its potential market approval.